Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

PDS Biotechnology

All the posts published.

NetScientific CEO to Present at Proactive Investors at 18:30 on the 7th December 2017

Dec 1, 2017
-
Glycotest, News, PDS Biotechnology, ProAxsis, Vortex BioSciences, Wanda Health

London, UK – 04 December 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group announces that Francois Martelet, Chief Executive Officer, will be presenting at the Proactive Investors Conference in London at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, on Thursday 07 December at 18:30 GMT   #  #  #   For more information, please contact:   NetScientific François R. Martelet, …

PDS Biotechnology Announces Clinical Collaboration with Merck & Co., Inc.

Jul 10, 2017
-
News, PDS Biotechnology, RNS Announcements

London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …

Executed Warrants

Dec 16, 2016
-
PDS Biotechnology, RNS Announcements

RNS Number : 0278S NetScientific PLC 16 December 2016 (“NetScientific” or the “Company” or the “Group”) NetScientific Executed Warrants in Portfolio Company, PDS Biotechnology, a new paradigm in cancer immunotherapy London, UK – 16 December 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that it has exercised warrants for 1,387,480 shares in its portfolio company, PDS Biotechnology. The total price …

Dr. Shepard, CMO of PDS Biotechnology, to Present PDS0101 Phase I/IIA Clinical Data at the Society for Immunotherapy of Cancer Meeting on November 11, 2016

Nov 9, 2016
-
PDS Biotechnology

Dr. Bedu-Addo to Chair the Therapeutics/Cancer Immunotherapies Session and Present Phase I/IIA Results

Sep 19, 2016
-
PDS Biotechnology

PDS Announces Agreement with FDA on Phase 2 Clinical Path for PDS0101

Aug 24, 2016
-
PDS Biotechnology

PDS Biotechnology Reports Positive Phase 1 Results

Apr 13, 2016
-
News, PDS Biotechnology, RNS Announcements

RNS Number : 0007V NetScientific PLC 13 April 2016 NetScientific plc (“NetScientific” or the “Company” or the “Group”)   NetScientific Portfolio Company PDS Biotechnology will embark on multiple Phase 2 studies following positive results following the completion of its Phase I study for PDS0101 Immunotherapy for HPV-Related Cancers   London, UK – 13/4/2016 – NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased …

PDS Biotechnology partners with NCI

Feb 9, 2016
-
News, PDS Biotechnology, RNS Announcements

RNS Number : 5158O NetScientific PLC 09 February 2016   NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …

PDS Biotechnology adds drug development executives

Jan 20, 2016
-
News, PDS Biotechnology, RNS Announcements

RNS Number : 4379M NetScientific PLC 20 January 2016 NetScientific plc   PDS Biotechnology appoints Chief Medical Officer and VP of Drug Development and Manufacturing to drive its clinical programmes   London, UK – 20 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes that its portfolio company, PDS Biotechnology, has appointed Dr. Robert Shepard, …

NetScientific invests in PDS Biotechnology

Dec 15, 2014
-
News, PDS Biotechnology, RNS Announcements

RNS Number : 7136Z NetScientific PLC 15 December 2014   NetScientific plc (‘NetScientific’ or ‘the Group’)    NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology   15 December 2014: NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).   PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more …

NetScientific Invests in Breakout Labs Companies

Jul 23, 2014
-
News, PDS Biotechnology

RNS Number : 0808N NetScientific PLC 23 July 2014     23 July 2014   NetScientific invests in a further two Breakout Labs portfolio companies     NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, is pleased to announce it has made a further two investments in portfolio companies from Breakout Labs, Peter Thiel’s revolving philanthropic fund that …

LOAD MORE POSTS
PDS Biotechnology Archives - NetScientific